AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AOP Health announced new results on ropeginterferon alfa2b BESREMi from its clinical study CONTINUATIONPV in patients with polycythaemia vera PV a rare blood cancer.